Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
Paul OsterLaurie VaillantErika RivaBrynn McMillanChristina BegkaCaroline TruntzerCorentin RichardMarine M LeblondMeriem MessaoudeneElisavet MachremiEmeric LimagneFrançois GhiringhelliBertrand RoutyGregory VerdeilDominique VelinPublished in: Gut (2021)
Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that H. pylori serology would be a powerful tool to personalize cancer immunotherapy treatment.